Hedge Funds Capture Big Early Gains in Select Biotech IPOs — With One Notable Exception

Major funds, including Suvretta, RA Capital, and Viking, took sizable stakes ahead of these offerings, positioning themselves to benefit from the sector’s strongest debuts.

Stephen Taub February 26, 2026

Several prominent hedge funds have realized significant returns on companies they had previously invested in that recently went public.For example, since Veradermics began trading publicly on February 3, its shares have surged nearly 150 percent. It describes itself as a late clinical-stage biopharmaceuticals company working

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2026 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.16.00 build:2026-02-25 Login